Google Translate Disclaimer
A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:
Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.
Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).
Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.
Effective August 30, 2022, the eligibility criteria for Paxlovid™ and remdesivir has been expanded to include an additional course of therapy for new and distinct COVID-19 infections in eligible patients.
Antiviral medications may be used in early treatment of mild to moderate COVID-19 illness in unvaccinated and certain vaccinated patients who are at high risk for progression to severe illness that may require hospitalization.
Antiviral treatments Paxlovid™ and remdesivir help reduce the viral load of COVID-19 virus in the body. They are not used to prevent COVID-19 infection before you test positive. Treatments are only effective when initiated in the very early phase of infection.
While most vaccinated people have enough immunity to fight COVID-19 infection, those that are unvaccinated, have a weaker immune system or are 70 years and older and at high risk of severe outcomes may benefit from antiviral therapy reducing the viral load that the immune system has to overcome.
Treatment for COVID-19 is Not a Substitute for Vaccination.
Treatment for COVID-19 does not offer equal protection to vaccination. Getting your first, second and all recommended booster doses remains the most important intervention to reduce risk of hospitalization and other severe outcomes from COVID-19. Find a vaccination clinic near you.
There is no cost for COVID-19 treatments in Saskatchewan.
Treatment with Paxlovid must start within five days of symptom onset. The medication consists of three tablets taken every 12 hours for five days.
The decision to prescribe an antiviral medication will be made by a pharmacists or HealthLine 811 taking into consideration patient risks, current medications, and underlying conditions.
Eligibility criteria is fairly strict and residents will be screened by their participating pharmacist, physician, nurse practitioner or through HealthLine 811 to ensure they meet the criteria.
Paxlovid is only recommended for adults over 18 who:
If you test positive for COVID-19 on a rapid antigen test or a PCR test and believe you may meet all the criteria for Paxlovid treatment, call a participating pharmacist, HealthLine 811 or a nurse practitioner. Stay home if you are ill and arrange for curbside pickup of medication if possible.
You cannot go directly to a health care provider to receive antiviral medication. You will be provided a prescription based on the eligibility criteria.
Effective August 30, 2022, the eligibility criteria for Paxlovid™ has been expanded to include an additional course of therapy for new and distinct COVID-19 infections in eligible patients.
Treatment with remdesivir must start within seven days of symptom onset. This is an intravenous treatment of at least 60 minutes for three, consecutive days.
The decision to prescribe remdesivir will be made by the treating clinician, taking into consideration patient risks, current medications, and underlying conditions.
A health care provider will review your symptoms, eligibility, and other factors to determine whether this treatment is appropriate.
Remdesivir is only recommended for adults over 18 who:
If you test positive for COVID-19 on a rapid antigen test or a PCR test and believe you may meet all the criteria for COVID-19 treatment, call HealthLine 811. You will receive additional screening and be referred appropriately.
You cannot receive remdesivir directly from your primary health care provider or through pharmacists. You must be referred based on the eligibility criteria.
Effective August 30, 2022, the eligibility criteria for remdesivir has been expanded to include an additional course of therapy for new and distinct COVID-19 infections in eligible patients.
Additional risk factors for those who are not fully vaccinated may include:
People who are fully vaccinated but otherwise immunocompromised could also be eligible for COVID-19 treatment. Immunocompromised conditions include, but are not limited to:
If you think you are eligible for Remdesivir or Paxlovid™ or if you have further questions, please call Healthline 811 to speak with a nurse.
Evusheld™ is a one-time treatment, which is administered by a qualified health care provider as two ventrogluteal intramuscular (IM) injections.
Evusheld™ is available in Saskatchewan for pre-exposure prophylaxis of COVID-19 in adults and adolescents (12 years of age or older), weighing at least 40 kg, who have NOT had a known recent exposure to an individual affected with COVID-19 and:
If Evusheld™ is being considered for use, it should be on a case-by-case basis where the potential benefit is expected to outweigh any potential risk. Consult your prescriber (physician or nurse practitioner) to discuss whether this is an option for you. Evusheld™ is only available if a prescription is issued by your prescriber.
In Saskatchewan, the case-by-case use of Evusheld™ should be limited to patients who:
At time of administration, confirm individual:
We need your feedback to improve saskatchewan.ca. Help us improve